45 anti-cancer drugs, 14 rare disease drugs, a big wave of imported drugs to reduce prices?

Recently, the Ministry of Finance, the General Administration of Customs, the General Administration of Taxation and the Drug Administration issued a second batch of anti-cancer drugs and rare disease drugs list, a total of 45 anti-cancer drugs and 14 rare disease drugs were included in the VAT tax reduction policy list. the
anti-cancer drug section, involving 39 preparations and 6 API, the preparation part includes: Pfizer non-small cell lung cancer targeted treatment drug dacotinyl tablets, local late stage or metastatic breast cancer treatment drug piresili, Hutchison Whampoa metastatic colorectal cancer treatment drug pyridoquine capsules, and AstraCon ovarian cancer targeted drug Olapani.
of the pharmaceutical preparations for rare diseases, there are 14 varieties, including: Sanofi's Teflon tablets for multiple sclerosis, Nosina's sodium injection for spinal muscular dystrophy, Jianzan's injection of Fabre's disease is based on aggaglyzyme β, Alexion's treatment of rare diseases in adults and children with bouts of sleep-based hemoglobinuria and atypical hemolytic uremia syndrome, etc.
In which the Nosinas sodium injection had previously been revealed to require 700,000 stitches at home, Ikuju monoantigen is also one of the world's most expensive drugs, which costs about $500,000 per year to treat in the United States and $700,000 per year per person in Canada.
both drugs are currently in the "qualified clinical urgent need for new drugs abroad" into the 2020 National Health Insurance Drug Catalog adjustment through the form of examination of the list of declared drugs.
In April 2018, the four departments issued the First Notice on the Value-Added Tax Policy on Anti-Cancer Drugs, and as of May 1, 2018, vat-added tax general taxpayers may choose to pay VAT at a simple rate of 3% in accordance with the simple method for the production, sale and wholesale and retail of anti-cancer drugs.
In February 2019, the Notice on VAT Policy for Rare Disease Drugs was issued, and as of March 1, 2019, VAT general taxpayers may choose to pay VAT at a simple rate of 3% for the production, sale and wholesale and retail of rare disease drugs.
this release list is the second batch of anti-cancer drugs and rare disease drugs VAT tax reduction list.
the reduction in VAT will result in a direct reduction in the value of these clinical applications and the urgent need for imported medicines? At present, there is no clear statement of pharmaceutical companies.
, however, the dividends for pharmaceutical companies are real, with some saying the tax cut would save cash flow for production and sales companies.
the original enterprises need to pay import value-added tax, and then to the tax department for VAT deduction.
are now paying less tax on import value-added tax, and capital turnover is more flexible, saving operating costs.
At the same time, there are industry insiders pointed out that the tax reduction policy has shown a clear signal that the country hopes to develop production, circulation and payment of a number of related policies, reduce drug prices, improve drug access.
, the regulatory authorities also hope that through the introduction of imported drugs, so that domestic pharmaceutical companies healthy competition, to promote the development of local innovative pharmaceutical enterprises.